Drugs / RG6289
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT06996730 | Jul 2026 → Jun 2030 expected | early-onset autosomal dominant Alzheimer disease | Banner Health | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RG6289 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06996730 ↗ |
| Route | Oral | “Oral tablet” NCT06996730 ↗ |